Induced Proximity-Based Drug Discovery Summit

Memo

Since the start of the 20th century, there have been three major waves of innovation in drug discovery. We are now at the start of a fourth wave, multispecific medicines, that will pave the way for new treatments aimed at thousands of disease targets currently viewed as “undruggable”. By inducing proximity between two or more proteins, multispecifics can harness the power of biology to go well beyond what conventional drugs can achieve. As such, the inaugural Induced Proximity- Based Drug Discovery Summit arrives as the dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to seize the endless potential of induced proximity- based drug discovery strategies to develop novel therapies for paradigm changing multispecific drugs of the future. Join 100+ thought leaders of Chemically Biology, Screening Biology and Molecular Biology from the likes of Amgen, Ranok Therapeutics, Proxygen and more at the Induced Proximity- Based Drug Discovery Summit to advance your knowledge, differentiate your pipelines and be at the forefront of this new wave of innovation that will revolutionize drug discovery as currently known. Tickets https://go.evvnt.com/751228-2?pid=5569Brochure https://go.evvnt.com/751228-3?pid=5569 Prices:Conference Only USD 1999.00Conference + 1 Workshop USD 2348.00Conference + 2 Workshops USD 2697.00 Speakers: Ed Ha, Head of Chemistry & Bioconjugation, Angiex, Nancy Pryer, Chief Scientific Officer, Ambagon Therapeutics, Ryan Potts, Executive Director & Head of Induced Proximity Platform, Amgen, Derek J. Taylor, Associate Professor, Case Western Reserve University, Benjamin Stanton, Principal Investigator Abigail, Wexner Research Institute at Nationwide Children’s Hospital, Stuart L. Schreiber, Co-Founder, Broad Institute, Katelyn Cassidy, Senior Scientist, AstraZeneca, Eric Wang, Research Fellow, Dana-Farber Cancer Institute, Dirksen Bussiere, Sr. Director/ Head, Molecular Pharmacology (Quantitative and Structural Biology), Eli Lilly and Company, Radoslaw Nowak, Scientist, Dana-Farber Cancer Institute, Charles Lin, Senior Vice President – Biology, Kronos Bio, Jamie Kasuboski, Vice President, OMX Ventures, Cristina Mayor- Ruiz, Group Leader, IRB Barcelona, Jonathan Solomon, Associate Director, Novartis Institutes for Biomedical Research, Matthias Brand, VP Biology, Proxygen, Chad May, Senior Vice President, R&D, Maverick Therapeutics, Goutham Narla, Professor of Medicine, University of Michigan, Daniel Nomura, Professor of Chemical Biology, University of California, Berkeley, Kevin Foley, Chief Scientific Officer, Ranok Therapeutics Co. Ltd., Fleur Ferguson, Assistant Professor, University of California, San Diego, George Burslem, Assistant Professor, University of Pennsylvania, Ivan Dikic, Director of Institute of Biochemistry II, Goethe University Frankfurst, Katherine Donovan, Senior Scientist, Dana-Farber Cancer Institute, Christian Ottmann, Chief Technology Officer, Ambagon Therapeutics, Amit Chouhdary, Assistant Professor, Broad Institute, Harvard Medical School & Brigham and Women’s Hospital, Ashley Modell, Postdoctoral Researcher, Choudhary Lab, Broad Institute of MIT and Harvard, and Harvard Medical School Time: On Tuesday June 29, 2021 at 8:00 am (ends Thursday July 01, 2021 at 6:00 pm)